Investor Relations
Cassava Sciences, Inc. is a biopharmaceutical company that develops novel drugs.
Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease
Jul 29, 2021
Simufilam Significantly Improves Cognition in Patients with Alzheimer’s in Interim Analysis of Open-label Study at 9 Months Cognition Improved 3.0 Points on ADAS-Cog at 9 Months ( p
Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease
Jul 29, 2021
Simufilam Significantly Improved Biomarkers in Alzheimer’s Patients Treated for 6 Months Robust Improvements Seen in All Measured Biomarkers of Disease, Neurodegeneration and Neuroinflammation (p